Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Samples Clear all
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Ability of a Supplement to Increase Good Bacteria in the Human Intestine and Blood Sugar Levels

NCT01944904
View directory record Official record
Conditions
Pre-diabetic
Interventions
Sugar Pill, XOS 2.8
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

Targeted Fusion Biopsy of the Prostate

NCT02744534
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 10, 2026, 8:34 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

NCT07492160
View directory record Official record
Conditions
Pregnancy, Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

NCT02722343
View directory record Official record
Conditions
HIV
Interventions
Tenofovir intravaginal ring, Truvada
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

NCT02861300
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
Interventions
CB-839, Capecitabine
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 10, 2026, 8:34 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacotoxicology of Trichloroethylene Metabolites

NCT01128270
View directory record Official record
Conditions
Healthy
Interventions
Dichloroacetate environmental dose, Chloral Hydrate environmental dose, Dichloroacetate therapeutic dose, Chloral Hydrate therapeutic dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

NCT00544596
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
R-(-)-gossypol acetic acid, cisplatin, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Sioux Falls, South Dakota • La Crosse, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 10, 2026, 8:34 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperemesis Gravidarum Risk Reduction With Metformin

NCT07129473
View directory record Official record
Conditions
Hyperemesis Gravidarum
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Active, not recruiting Not applicable Interventional

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

NCT03881098
View directory record Official record
Conditions
Lung Cancer
Interventions
Bronchoscopies, Sputum Sample, Venipuncture
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Recruiting No phase listed Observational

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

NCT05995821
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer
Interventions
Collection of biological specimens
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional

Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease

NCT04828031
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Vitamin D
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

NCT03326102
View directory record Official record
Conditions
Recurrent or Metastatic Breast Cancer
Interventions
DHP107, IV Paclitaxel
Drug
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 10, 2026, 8:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of An Oral Fluid Collection Device

NCT02026440
View directory record Official record
Conditions
Smoking
Interventions
Not listed
Lead sponsor
Avioq, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2014 · Synced Sep 10, 2026, 8:34 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional

FMT for Postop Crohn's Disease

NCT05248191
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule fecal microbiota material (cap-FMT), Colonoscopic fecal microbiota material (colo-FMT)
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274
View directory record Official record
Conditions
Bioequivalence
Interventions
Tacrolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 10, 2026, 8:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 10, 2026, 8:34 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Glycemic Index of Commonly Consumed Sweeteners

NCT02931578
View directory record Official record
Conditions
Healthy
Interventions
Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 10, 2026, 8:34 AM EDT
Completed No phase listed Observational

Oral Alkali Production and Caries Prevention in Children (Longitudinal)

NCT02398695
View directory record Official record
Conditions
Dental Caries
Interventions
Oral Samples
Other
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 7 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 10, 2026, 8:34 AM EDT
Completed Phase 1 Interventional

Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus

NCT02755064
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Erythromycin lactobionate, Placebo IV, [13C]-Spirulina, Erythromycin Ethylsuccinate Suspension, Placebo Suspension
Drug
Lead sponsor
Adil Bharucha
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 10, 2026, 8:34 AM EDT